131 related articles for article (PubMed ID: 36921457)
1. Integration of mRNA and protein expression data for the identification of potential biomarkers associated with pancreatic ductal adenocarcinoma.
Akrami S; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
Comput Biol Med; 2023 May; 157():106529. PubMed ID: 36921457
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
3. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
4. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
5. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
6. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
7. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.
Lu Y; Li C; Chen H; Zhong W
Mol Biol Rep; 2018 Dec; 45(6):1799-1807. PubMed ID: 30173393
[TBL] [Abstract][Full Text] [Related]
8. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
9. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.
Zhou M; Diao Z; Yue X; Chen Y; Zhao H; Cheng L; Sun J
Oncotarget; 2016 Aug; 7(35):56383-56394. PubMed ID: 27487139
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
11. Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.
Wu Y; Wei J; Ming Y; Chen Z; Yu J; Mao R; Chen H; Zhou G; Fan Y
J Cell Biochem; 2018 Sep; 119(9):7696-7706. PubMed ID: 29923223
[TBL] [Abstract][Full Text] [Related]
12. The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma.
Luan H; He Y; Zhang T; Su Y; Zhou L
BMC Cancer; 2022 Apr; 22(1):463. PubMed ID: 35477379
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
14. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
16. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
[TBL] [Abstract][Full Text] [Related]
17. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.
Yang C; Yu T; Liu Z; Ye X; Liao X; Wang X; Han C; Zhu G; Qin W; Peng T
Oncol Rep; 2019 Jul; 42(1):79-90. PubMed ID: 31059105
[TBL] [Abstract][Full Text] [Related]
18. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer.
Giulietti M; Righetti A; Principato G; Piva F
Carcinogenesis; 2018 Jul; 39(8):1016-1025. PubMed ID: 29796634
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.
Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y
Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694
[TBL] [Abstract][Full Text] [Related]
20. Identification and verification of CCNB1 as a potential prognostic biomarker by comprehensive analysis.
Zeng Y; Fan R
Sci Rep; 2022 Sep; 12(1):16153. PubMed ID: 36167975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
